Game-Changer for Obesity: Weight Loss Drug Mounjaro Set to Launch in India by 2025 [Video]

Eli Lilly, a leading US pharmaceutical company, is gearing up to launch its groundbreaking diabetes and obesity medication, Tirzepatide—commercially known as Mounjaro—in India by 2025. The drug has garnered widespread attention for its efficacy in addressing both type 2 diabetes and obesity. With marketing authorizations already secured, the company is now working through final regulatory approvals before introducing this innovative solution to the Indian market.

Affordable Accessibility: Eli Lilly’s Vision for India

Eli Lilly has emphasized its commitment to ensuring that Mounjaro is accessible to those in need. The company plans to implement a “competitive and appropriate” pricing strategy tailored for India, reflecting the drug’s efficacy in reducing the health and economic burden of chronic conditions like diabetes and obesity.

“We aim to launch Tirzepatide in India by 2025 after obtaining necessary regulatory approvals,” a company spokesperson stated.